Jason C. Chang

发表

MET Exon 14–altered Lung Cancers and MET Inhibitor Resistance

A. Drilon, C. Rudin, M. Kris, 2020, Clinical Cancer Research.

MET-dependent solid tumours — molecular diagnosis and targeted therapy

A. Drilon, M. Arcila, N. Rekhtman, 2020, Nature Reviews Clinical Oncology.

Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma.

A. Drilon, M. Kris, R. Benayed, 2020, Clinical lung cancer.

H&E-based Computational Biomarker Enables Universal EGFR Screening for Lung Adenocarcinoma

Chad M. Vanderbilt, Gabriele Campanella, I. Häggström, 2022, ArXiv.

Stage IV Lung Carcinoids: Spectrum and Evolution of Proliferation Rate, Focusing on Variants with Elevated Proliferation Indices

M. Ladanyi, C. Rudin, W. Travis, 2019, Modern Pathology.

Insights into pathogenesis of fatal COVID‐19 pneumonia from histopathology with immunohistochemical and viral RNA studies

W. Travis, S. Pittaluga, S. Morjaria, 2020, Histopathology.

CNS Metastases in Patients With MET Exon 14-Altered Lung Cancers and Outcomes With Crizotinib.

M. Ladanyi, A. Drilon, C. Rudin, 2020, JCO precision oncology.

Small Cell Lung Carcinoma Subtypes Defined by ASCL1, NEUROD1, POU2F3 and YAP1: Comprehensive Immunohistochemical and Histopathologic Characterization.

C. Rudin, W. Travis, N. Rekhtman, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

FGFR2::TACC2 fusion as a novel KIT‐independent mechanism of targeted therapy failure in a multidrug‐resistant gastrointestinal stromal tumor

Chad M. Vanderbilt, C. Antonescu, S. Singer, 2022, Genes, chromosomes & cancer.

Successful Use of Afatinib After Erlotinib‐induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor‐mutant Lung Cancer

N. Rekhtman, P. Paik, A. Iqbal, 2017, Clinical lung cancer.

Comprehensive detection of targetable fusions in lung adenocarcinomas by complementary targeted DNAseq and RNAseq assays.

M. Ladanyi, M. Berger, A. Drilon, 2018 .

RUNX2 (6p21.1) amplification in osteosarcoma.

M. Ladanyi, K. Nafa, M. Hameed, 2019, Human pathology.

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

David R. Jones, N. Schultz, M. Ladanyi, 2021, Nature Medicine.

POU2F3 in SCLC: Clinicopathologic and genomic analysis with a focus on its diagnostic utility in neuroendocrine-low SCLC.

M. Ladanyi, C. Antonescu, C. Rudin, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation

C. Rudin, J. Silber, C. Iacobuzio-Donahue, 2020, bioRxiv.

Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes

L. Borsu, M. Ladanyi, A. Drilon, 2021, Clinical Cancer Research.

Invasive Mucinous Adenocarcinomas with Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling.

L. Borsu, M. Ladanyi, A. Drilon, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Bronchiolar Adenoma/Pulmonary Ciliated Muconodular Papillary Tumor.

M. Mino‐Kenudson, A. Saqi, N. Rekhtman, 2020, American journal of clinical pathology.

The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

B. Taylor, M. Ladanyi, C. Rudin, 2020, Clinical Cancer Research.

Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma

M. Ladanyi, W. Travis, N. Rekhtman, 2020, Modern Pathology.

SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas

David R. Jones, M. Ladanyi, C. Rudin, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements

L. Borsu, M. Ladanyi, C. Antonescu, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lobectomy Is Associated with Better Outcomes than Sublobar Resection in Spread through Air Spaces (STAS)‐Positive T1 Lung Adenocarcinoma: A Propensity Score–Matched Analysis

David R. Jones, W. Travis, N. Rekhtman, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Bronchiolar Adenoma: Expansion of the Concept of Ciliated Muconodular Papillary Tumors With Proposal for Revised Terminology Based on Morphologic, Immunophenotypic, and Genomic Analysis of 25 Cases

L. Borsu, M. Ladanyi, W. Travis, 2018, The American journal of surgical pathology.

Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.

M. Ladanyi, A. Drilon, C. Rudin, 2018, Cancer discovery.

A Pan-Cancer Study of Somatic TERT Promoter Mutations and Amplification in 30,773 Tumors Profiled By Clinical Genomic Sequencing.

Chad M. Vanderbilt, M. Ladanyi, M. Berger, 2020, The Journal of molecular diagnostics : JMD.

Are there imaging characteristics that can distinguish separate primary lung carcinomas from intrapulmonary metastases using next-generation sequencing as a gold standard?

V. Rusch, R. Perez-Johnston, N. Rekhtman, 2021, Lung cancer.

High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden

M. Ladanyi, M. Berger, A. Drilon, 2019, Clinical Cancer Research.

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer

D. Pe’er, M. Ladanyi, M. Kris, 2020, Clinical Cancer Research.

Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway

Steven J. M. Jones, Mauro A. A. Castro, Benjamin J. Raphael, 2021, Cell reports.

Lung Carcinoma

M. Arcila, L. Tafe, Jason C. Chang, 2019, Genomic Medicine.

Defining Novel DNA Virus-Tumor Associations and Genomic Correlates using Prospective Clinical Tumor/Normal Matched Sequencing Data.

M. Ladanyi, M. Berger, M. Arcila, 2022, The Journal of molecular diagnostics : JMD.

Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach

David R. Jones, V. Seshan, M. Ladanyi, 2019, Clinical Cancer Research.

JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy.

Chad M. Vanderbilt, M. Ladanyi, Laura H. Tang, 2019, Human pathology.

Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management.

Chad M. Vanderbilt, M. Ladanyi, M. Berger, 2019, The Journal of molecular diagnostics : JMD.

Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS

Julie L. Yang, M. Ladanyi, M. Berger, 2021, Nature Communications.

Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assay

Julie L. Yang, M. Ladanyi, M. Berger, 2020, bioRxiv.

Spectrum of BRAF Mutations and Gene Rearrangements in Ovarian Serous Carcinoma

A. Drilon, B. Weigelt, A. Zehir, 2021, JCO precision oncology.

Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases

A. Drilon, M. Kris, N. Rekhtman, 2019, JCO precision oncology.

Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation

C. Rudin, N. Rekhtman, U. Bhanot, 2021, Journal of Hematology & Oncology.

Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers.

M. Ladanyi, A. Drilon, C. Rudin, 2018, JCO precision oncology.

Clinical utility and performance of an ultra-rapid multiplex RNA-based assay for detection of ALK, ROS1, RET and NTRK1/2/3 rearrangements and MET exon 14 skipping alterations.

M. Ladanyi, M. Arcila, K. Nafa, 2022, The Journal of molecular diagnostics : JMD.

First Report of Thoracic Carcinoma With DEK::AFF2 Rearrangement: A Case Report.

F. Askin, N. Rekhtman, J. Bishop, 2022, Journal of Thoracic Oncology.

Type A thymoma presenting with bone metastasis

C. Antonescu, W. Travis, M. Bains, 2018, Histopathology.

Rapid EGFR Mutation Detection Using the Idylla Platform: Single institution experience of 1200 cases analyzed by an in-house developed pipeline and comparison with concurrent next-generation sequencing results.

M. Ladanyi, W. Travis, M. Arcila, 2020, The Journal of molecular diagnostics : JMD.

MA12.05 Can Tumor Spread through Air Spaces (STAS) in Lung Adenocarcinomas Be Predicted Pre- and Intraoperatively?

David R. Jones, W. Travis, N. Rekhtman, 2017 .

Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers.

D. Pe’er, M. Ladanyi, M. Kris, 2019, Journal of Clinical Oncology.

Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation.

C. Rudin, J. Silber, C. Iacobuzio-Donahue, 2021, Cancer Discovery.

Mechanisms of acquired resistance to TRK inhibitors.

A. Drilon, Y. Murciano-Goroff, A. Schram, 2022, Journal of Clinical Oncology.

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

David R. Jones, N. Schultz, M. Ladanyi, 2022, Nature Medicine.

Targeting NFE2L2/KEAP1 mutations in advanced non-small cell lung cancer with the TORC1/2 inhibitor TAK-228.

M. Ladanyi, C. Rudin, P. Paik, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.